Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.

Salaroglio IC, Abate C, Rolando B, Battaglia L, Gazzano E, Colombino E, Costamagna C, Annovazzi L, Mellai M, Berardi F, Capucchio MT, Schiffer D, Riganti C.

Mol Pharm. 2019 Aug 5;16(8):3361-3373. doi: 10.1021/acs.molpharmaceut.9b00018. Epub 2019 Jul 2.

PMID:
31265310
2.

SEL1L plays a major role in human malignant gliomas.

Mellai M, Annovazzi L, Boldorini R, Bertero L, Cassoni P, De Blasio P, Biunno I, Schiffer D.

J Pathol Clin Res. 2019 May 20. doi: 10.1002/cjp2.134. [Epub ahead of print]

3.

Glioblastoma: Microenvironment and Niche Concept.

Schiffer D, Annovazzi L, Casalone C, Corona C, Mellai M.

Cancers (Basel). 2018 Dec 20;11(1). pii: E5. doi: 10.3390/cancers11010005. Review.

4.

Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.

Salaroglio IC, Mujumdar P, Annovazzi L, Kopecka J, Mellai M, Schiffer D, Poulsen SA, Riganti C.

Mol Cancer Ther. 2018 Dec;17(12):2598-2609. doi: 10.1158/1535-7163.MCT-18-0533. Epub 2018 Sep 25.

PMID:
30254183
5.

Correction: SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.

Mellai M, Cattaneo M, Storaci AM, Annovazzi L, Cassoni P, Melcarne A, De Blasio P, Schiffer D, Biunno I.

Oncotarget. 2018 Aug 24;9(66):32731. doi: 10.18632/oncotarget.26066. eCollection 2018 Aug 24.

6.

The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.

Schiffer D, Mellai M, Boldorini R, Bisogno I, Grifoni S, Corona C, Bertero L, Cassoni P, Casalone C, Annovazzi L.

Int J Mol Sci. 2018 Sep 12;19(9). pii: E2724. doi: 10.3390/ijms19092724. Review.

7.

Glioblastoma niches: from the concept to the phenotypical reality.

Schiffer D, Mellai M, Bovio E, Bisogno I, Casalone C, Annovazzi L.

Neurol Sci. 2018 Jul;39(7):1161-1168. doi: 10.1007/s10072-018-3408-0. Epub 2018 May 8. Review.

PMID:
29736738
8.

Microglia immunophenotyping in gliomas.

Annovazzi L, Mellai M, Bovio E, Mazzetti S, Pollo B, Schiffer D.

Oncol Lett. 2018 Jan;15(1):998-1006. doi: 10.3892/ol.2017.7386. Epub 2017 Nov 9.

9.

Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.

Clemente N, Ferrara B, Gigliotti CL, Boggio E, Capucchio MT, Biasibetti E, Schiffer D, Mellai M, Annovazzi L, Cangemi L, Muntoni E, Miglio G, Dianzani U, Battaglia L, Dianzani C.

Int J Mol Sci. 2018 Jan 24;19(2). pii: E255. doi: 10.3390/ijms19020255.

10.

Comparison among conventional and advanced MRI, 18F-FDG PET/CT, phenotype and genotype in glioblastoma.

Valentini MC, Mellai M, Annovazzi L, Melcarne A, Denysenko T, Cassoni P, Casalone C, Maurella C, Grifoni S, Fania P, Cistaro A, Schiffer D.

Oncotarget. 2017 Oct 4;8(53):91636-91653. doi: 10.18632/oncotarget.21482. eCollection 2017 Oct 31.

11.

The neuropathological basis to the functional role of microglia/macrophages in gliomas.

Schiffer D, Mellai M, Bovio E, Annovazzi L.

Neurol Sci. 2017 Sep;38(9):1571-1577. doi: 10.1007/s10072-017-3002-x. Epub 2017 Jun 7. Review.

PMID:
28593528
12.

Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.

Annovazzi L, Mellai M, Schiffer D.

Cancers (Basel). 2017 May 26;9(6). pii: E57. doi: 10.3390/cancers9060057. Review.

13.

Comparison of Allogeneic and Syngeneic Rat Glioma Models by Using MRI and Histopathologic Evaluation.

Biasibetti E, Valazza A, Capucchio MT, Annovazzi L, Battaglia L, Chirio D, Gallarate M, Mellai M, Muntoni E, Peira E, Riganti C, Schiffer D, Panciani P, Lanotte M.

Comp Med. 2017 Mar 1;67(2):147-156.

14.

Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment.

Battaglia L, Muntoni E, Chirio D, Peira E, Annovazzi L, Schiffer D, Mellai M, Riganti C, Salaroglio IC, Lanotte M, Panciani P, Capucchio MT, Valazza A, Biasibetti E, Gallarate M.

Nanomedicine (Lond). 2017 Mar;12(6):639-656. doi: 10.2217/nnm-2016-0380. Epub 2017 Feb 10.

PMID:
28186465
15.

A comprehensive view of tumor stem cells and their regulation by the microenvironment in glioblastoma.

Schiffer D, Annovazzi L, Mellai M.

Neurol Sci. 2017 Mar;38(3):527-529. doi: 10.1007/s10072-016-2768-6. Epub 2016 Nov 16. No abstract available.

PMID:
27853910
16.

Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.

Mellai M, Annovazzi L, Senetta R, Dell'Aglio C, Mazzucco M, Cassoni P, Schiffer D.

J Neurooncol. 2017 Jan;131(2):213-222. doi: 10.1007/s11060-016-2296-5. Epub 2016 Oct 28.

PMID:
27796734
17.

Mesenchymal/radioresistant traits in granular astrocytomas: evidence from a combined clinical and molecular approach.

Senetta R, Mellai M, Manini C, Castellano I, Bertero L, Pittaro A, Schiffer D, Boldorini R, Cassoni P.

Histopathology. 2016 Aug;69(2):329-37. doi: 10.1111/his.12944. Epub 2016 Mar 21.

PMID:
26845757
18.

WNT/β-catenin Signaling Pathway and Downstream Modulators in Low- and High-grade Glioma.

Denysenko T, Annovazzi L, Cassoni P, Melcarne A, Mellai M, Schiffer D.

Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):31-45.

19.

The Microenvironment in Gliomas: Phenotypic Expressions.

Schiffer D, Annovazzi L, Mazzucco M, Mellai M.

Cancers (Basel). 2015 Dec 3;7(4):2352-9. doi: 10.3390/cancers7040896.

20.

SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.

Mellai M, Cattaneo M, Storaci AM, Annovazzi L, Cassoni P, Melcarne A, De Blasio P, Schiffer D, Biunno I.

Oncotarget. 2015 May 20;6(14):12452-67. Erratum in: Oncotarget. 2018 Aug 24;9(66):32731.

21.

The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.

Annovazzi L, Caldera V, Mellai M, Riganti C, Battaglia L, Chirio D, Melcarne A, Schiffer D.

Int J Oncol. 2015;46(6):2299-308. doi: 10.3892/ijo.2015.2963. Epub 2015 Apr 16.

22.

Astroblastoma: beside being a tumor entity, an occasional phenotype of astrocytic gliomas?

Mellai M, Piazzi A, Casalone C, Grifoni S, Melcarne A, Annovazzi L, Cassoni P, Denysenko T, Valentini MC, Cistaro A, Schiffer D.

Onco Targets Ther. 2015 Feb 19;8:451-60. doi: 10.2147/OTT.S71384. eCollection 2015.

23.

Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment.

Chirio D, Gallarate M, Peira E, Battaglia L, Muntoni E, Riganti C, Biasibetti E, Capucchio MT, Valazza A, Panciani P, Lanotte M, Annovazzi L, Caldera V, Mellai M, Filice G, Corona S, Schiffer D.

Eur J Pharm Biopharm. 2014 Nov;88(3):746-58.

24.

Stem cell niches in glioblastoma: a neuropathological view.

Schiffer D, Mellai M, Annovazzi L, Caldera V, Piazzi A, Denysenko T, Melcarne A.

Biomed Res Int. 2014;2014:725921. doi: 10.1155/2014/725921. Epub 2014 Apr 15.

25.

Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies.

Battaglia L, Gallarate M, Peira E, Chirio D, Muntoni E, Biasibetti E, Capucchio MT, Valazza A, Panciani PP, Lanotte M, Schiffer D, Annovazzi L, Caldera V, Mellai M, Riganti C.

J Pharm Sci. 2014 Jul;103(7):2157-2165. doi: 10.1002/jps.24002. Epub 2014 May 13.

26.

Repressor element-1 silencing transcription factor (REST) is present in human control and Huntington's disease neurones.

Schiffer D, Caldera V, Mellai M, Conforti P, Cattaneo E, Zuccato C.

Neuropathol Appl Neurobiol. 2014 Dec;40(7):899-910. doi: 10.1111/nan.12137.

PMID:
24634989
27.

Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid.

Cattaneo M, Baronchelli S, Schiffer D, Mellai M, Caldera V, Saccani GJ, Dalpra L, Daga A, Orlandi R, DeBlasio P, Biunno I.

J Biol Chem. 2014 Jan 31;289(5):2826-38. doi: 10.1074/jbc.M113.527754. Epub 2013 Dec 5.

28.

Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.

Mellai M, Piazzi A, Caldera V, Annovazzi L, Monzeglio O, Senetta R, Cassoni P, Schiffer D.

Biomed Res Int. 2013;2013:756302. doi: 10.1155/2013/756302. Epub 2013 Sep 3.

29.

Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.

Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Bosia A, Ghigo D, Schiffer D.

Neuro Oncol. 2013 Nov;15(11):1502-17. doi: 10.1093/neuonc/not104. Epub 2013 Jul 28.

30.

Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling.

Riganti C, Salaroglio IC, Pinzòn-Daza ML, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Couraud PO, Bosia A, Ghigo D, Schiffer D.

Cell Mol Life Sci. 2014 Feb;71(3):499-516. doi: 10.1007/s00018-013-1397-y. Epub 2013 Jun 15.

31.

MGMT hypermethylation and MDR system in glioblastoma cancer stem cells.

Caldera V, Mellai M, Annovazzi L, Monzeglio O, Piazzi A, Schiffer D.

Cancer Genomics Proteomics. 2012 Jul-Aug;9(4):171-8.

PMID:
22798502
32.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
33.

Antigenic and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres.

Caldera V, Mellai M, Annovazzi L, Piazzi A, Lanotte M, Cassoni P, Schiffer D.

J Oncol. 2011;2011:314962. doi: 10.1155/2011/314962. Epub 2011 Aug 18.

34.

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.

J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4.

PMID:
21643842
35.

SOX2 expression and amplification in gliomas and glioma cell lines.

Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D.

Cancer Genomics Proteomics. 2011 May-Jun;8(3):139-47.

PMID:
21518820
36.

PNET/ESFT of the cranial vault: a case report.

Mellai M, Caldera V, Comino A, Fortunato M, Bernucci C, Schiffer D.

Clin Neuropathol. 2010 Nov-Dec;29(6):372-7.

PMID:
21073841
37.

On the origin and growth of gliomas.

Schiffer D, Annovazzi L, Caldera V, Mellai M.

Anticancer Res. 2010 Jun;30(6):1977-98. Review.

PMID:
20651342
38.

mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma.

Annovazzi L, Mellai M, Caldera V, Valente G, Tessitore L, Schiffer D.

Anticancer Res. 2009 Aug;29(8):3087-94.

39.

MGMT promoter hypermethylation in a series of 104 glioblastomas.

Mellai M, Caldera V, Annovazzi L, Chiò A, Lanotte M, Cassoni P, Finocchiaro G, Schiffer D.

Cancer Genomics Proteomics. 2009 Jul-Aug;6(4):219-27.

40.

Survivin expression in glioblastomas correlates with proliferation, but not with apoptosis.

Mellai M, Caldera V, Patrucco A, Annovazzi L, Schiffer D.

Anticancer Res. 2008 Jan-Feb;28(1A):109-18.

41.

Stat3 expression and its correlation with proliferation and apoptosis/autophagy in gliomas.

Caldera V, Mellai M, Annovazzi L, Valente G, Tessitore L, Schiffer D.

J Oncol. 2008;2008:219241. doi: 10.1155/2008/219241. Epub 2009 Apr 27.

42.

Apoptosis in brain tumors: prognostic and therapeutic considerations.

Mellai M, Schiffer D.

Anticancer Res. 2007 Jan-Feb;27(1A):437-48. Review.

43.

A family-based study does not confirm the association of MYO9B with celiac disease in the Italian population.

Giordano M, Marano C, Mellai M, Limongelli MG, Bolognesi E, Clerget-Darpoux F, Momigliano-Richiardi P, Greco L.

Genes Immun. 2006 Oct;7(7):606-8. Epub 2006 Aug 31.

PMID:
16943798
44.

A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population.

Liguori M, Sawcer S, Setakis E, Compston A, Giordano M, D'Alfonso S, Mellai M, Malferrari G, Trojano M, Livrea P, De Robertis F, Massacesi L, Repice A, Ballerini C, Biagioli T, Bomprezzi R, Cannoni S, Ristori G, Salvetti M, Grimaldi LM, Biunno I, Comi G, Leone M, Ferro I, Naldi P, Milanese C, Gellera C, Loredana LM, Savettieri G, Salemi G, Aridon P, Caputo D, Rosa Guerini F, Ferrante P, Momigliano-Richiardi P.

J Neuroimmunol. 2003 Oct;143(1-2):97-100.

PMID:
14575923
45.

Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus.

Mellai M, Giordano M, D'Alfonso S, Marchini M, Scorza R, Danieli M.G., Leone M, Ferro I, Liguori M, Trojano M, Ballerini C, Massacesi L, Cannoni S, Bomprezzi R, Momigliano-Richiardi P.

Hum Immunol. 2003 Feb;64(2):274-84.

PMID:
12559630
46.

Association tests with systemic lupus erythematosus (SLE) of IL10 markers indicate a direct involvement of a CA repeat in the 5' regulatory region.

D' Alfonso S, Giordano M, Mellai M, Lanceni M, Barizzone N, Marchini M, Scorza R, Danieli MG, Cappelli M, Rovere P, Sabbadini MG, Momigliano-Richiardi P.

Genes Immun. 2002 Dec;3(8):454-63.

47.

Identification of single nucleotide variations in the coding and regulatory regions of the myelin-associated glycoprotein gene and study of their association with multiple sclerosis.

D'Alfonso S, Mellai M, Giordano M, Pastore A, Malferrari G, Naldi P, Repice A, Liguori M, Cannoni S, Milanese C, Caputo D, Savettieri G, Momigliano-Richiardi P; Italian Group for the Study of Multiple Sclerosis Genetics.

J Neuroimmunol. 2002 May;126(1-2):196-204.

PMID:
12020971
48.

The IL12B gene does not confer susceptibility to coeliac disease.

Louka AS, Torinsson Naluai A, D'Alfonso S, Ascher H, Coto I, Ek J, Giordano M, Gudjónsdóttir AH, Mellai M, Momigliano-Richiardi P, Percopo S, Samuelsson L, Wahlström J, Greco L, Sollid LM.

Tissue Antigens. 2002 Jan;59(1):70-2.

PMID:
11972887
49.

Determination of SNP allele frequencies in pooled DNAs by primer extension genotyping and denaturing high-performance liquid chromatography.

Giordano M, Mellai M, Hoogendoorn B, Momigliano-Richiardi P.

J Biochem Biophys Methods. 2001 Jan 30;47(1-2):101-10.

PMID:
11179766

Supplemental Content

Loading ...
Support Center